Tiazotic acid explained
| Drug Name: | Tiazotic acid |
| Tradename: | Thiotriazoline; Tiokor |
| Cas Number: | 64679-65-8 |
| Cas Supplemental: |
357172-63-5 (morpholine salt) |
| Pubchem: | 254566 |
| Unii: | YEZ00M9XKN |
| Kegg: | D10852 |
| Chembl: | 1487672 |
| Iupac Name: | 2-[(5-Methyl-1''H''-1,2,4-triazol-3-yl)sulfanyl]acetic acid |
| C: | 5 |
| H: | 7 |
| N: | 3 |
| O: | 2 |
| S: | 1 |
| Smiles: | CC1=NC(=NN1)SCC(=O)O |
| Stdinchi: | InChI=1S/C5H7N3O2S/c1-3-6-5(8-7-3)11-2-4(9)10/h2H2,1H3,(H,9,10)(H,6,7,8) |
| Stdinchikey: | OJUNWHNRDPRNBR-UHFFFAOYSA-N |
Tiazotic acid (brand names Thiotriazoline and Tiokor) is an antioxidant. It is used as a pharmaceutical drug for the treatment of ischemic heart disease in Russia, Ukraine, and Uzbekistan.[1] [2]
It is used as its salt with morpholine.[3]
It has been studied for its potential to improve the cardiac effects of COVID-19.[4]
Notes and References
- Web site: Tiazotic acid . National Center for Advancing Translational Sciences . Inxsight Drugs .
- Kadin DV, Chumak BA, Filippov AE, Shustov SB . [Thiotriazoline in the Treatment of Stable Angina Pectoris of II-III Functional Class] . Kardiologiia . 55 . 8 . 26–29 . 2015 . 26761968 . 10.18565/cardio.2015.8.26-29 .
- 10.1039/C7CE00117G . The formation of two thiotriazoline polymorphs: Study from the energetic viewpoint . 2017 . Shishkina SV, Baumer VN, Khromileva OV, Kucherenko LI, Mazur IA . CrystEngComm . 19 . 17 . 2394–2401 .
- 10.3897/pharmacia.69.e82596 . free . Therapy of post-COVID-19 syndrome: Improving the efficiency and safety of basic metabolic drug treatment with tiazotic acid (Thiotriazoline) . 2022 . Belenichev I, Kucherenko L, Pavlov S, Bukhtiyarova N, Popazova O, Derevianko N, Nimenko G . Pharmacia . 69 . 2 . 509–516 .
